Karen Soussan-Lazard

Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: Prespecified subgroup analyses from the VELOUR trial

Josep Tabernero, Eric Van Cutsem, Radek Lakomý et al. · European Journal of Cancer · 2013 · 238 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Phase I Dose-Escalation Study of Intravenous Aflibercept in Combination with Docetaxel in Patients with Advanced Solid Tumors

Nicolás Isambert, Gilles Freyer, Sylvie Zanetta et al. · Clinical Cancer Research · 2012 · 44 citations

Medicine, Oncology, Pharmacology +15

Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours

Eric Van Cutsem, David Khayat, Chris Verslype et al. · European Journal of Cancer · 2012 · 36 citations · Full text

Medicine, Oncology, Pharmacology +14

Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial

Paul Ruff, Eric Van Cutsem, Radek Lakomý et al. · Journal of Geriatric Oncology · 2017 · 35 citations

Medicine, Oncology, Pharmacology +11

Results From VELOUR, a Phase 3 Study of Aflibercept (A) Versus Placebo (pbo) in Combination with FOLFIRI for the Treatment of Patients (pt) with Previously Treated Metastatic Colorectal Cancer (MCRC)

Josep Tabernero, Eric Van Cutsem, Radek Lakomý et al. · European Journal of Cancer · 2011 · 33 citations

Medicine, Oncology, Pharmacology +11